Newsstand | Page 27 | Aplastic Anemia & MDS International Foundation Return to top.


Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

MDS Update - February 2017

Originally Published: 02/01/2017
MDS Update - February 2017

MDS expert finds promising antibody

Originally Published: 01/25/2017
A protein-sugar molecule, CD99, occurs more frequently than normal on stem cells responsible for blood cancers, including acute myeloid leukemia (AML) and the related myelodysplastic syndromes (MDS). This is the finding of a study led by researchers from NYU Langone Medical Center and Memorial Sloan Kettering Cancer Center, and published online Jan. 25 in Science Translational Medicine. Building on this discovery, the study authors designed an antibody that recognizes and destroys CD99-covered leukemia cells while sparing normal blood stem cells, a finding confirmed by experiments in human...

DC Walk a Winner Despite Wicked Cold

Originally Published: 01/18/2017
Late Wrap-Up Due to Virtual Walk Component, Which Ran through Dec. 31 Frigid temperatures and a 7 a.m. start time didn’t dampen the enthusiasm of the 221 people [and a few assorted hounds] who showed up to run, jog and walk at East Potomac Park for our very first National March for Marrow DC. In fact, the winner of the 5K race was also the very first runner to arrive in the pre-dawn dark on Dec.10, and he wasn’t even wearing a hat or coat! He kept warm by volunteering to help us set up, and we returned the favor by wrapping him in an AAMDSIF blanket. After registration, team photos and...

AAMDSIF Merger with PNHF Finalized

Originally Published: 01/13/2017
Dear Community, This month, AAMDSIF finalized its merger with the PNH Research and Support Foundation that we first announced to you on Nov. 1. When nonprofit allies share a long history of successful engagement for the same cause, it stands to reason that they’ll get married someday. After years of close collaboration, it was clear to both organizations that by joining forces, we will become stronger together – as well as more efficient and effective in the services and support we provide to our patients and families. In much the same way that each of you are stronger by virtue of being...

New positive results for GVHD treatment

Originally Published: 01/12/2017
The targeted cancer therapy ibrutinib (Imbruvica®) can effectively treat a common and serious complication of a type of stem cell transplant, findings from a small clinical trial show. Patients in the trial had blood cancers and were experiencing symptoms of chronic graft-versus-host disease (GVHD) after receiving a transplant of donated blood stem cells, known as an allogeneic transplant. The patients’ symptoms—including widespread skin rashes and painful mouth ulcers—had persisted despite standard treatment with corticosteroids. Following treatment with ibrutinib, approximately two-thirds...

Rare disease topic tackled by World Economic Forum

Originally Published: 01/12/2017
Responsive and responsible leadership is the central theme of this year’s World Economic Forum meeting in Davos. For the biopharma industry, I believe our core contribution is innovation: we must focus on developing new medicines that address unmet medical needs and deliver value for all of those affected. Rare diseases pose a significant medical and economic burden for patients, communities and healthcare systems. A rare disease, sometimes referred to as an orphan disease, is any disease that affects a small percentage of the general population. In the US, a condition is considered rare...

Dr. Dave rocks at Childrens Hospital of Wisconsin

Originally Published: 01/05/2017

AAMDSIF Activities at ASH 2016

Originally Published: 12/14/2016
Satellite Symposium For the 9th consecutive year, AAMDSIF sponsored a satellite symposium at ASH in partnership with Cleveland Clinic. This year’s symposium, “Clinical Management of MDS/MPN:  A Mountain of Evidence for Treatment Selection in MDS/MPN” provided an in-depth review of research related to the biology, prognosis, natural history and therapeutic management of patients with MDS, MPN and MDS/MPN overlap.  The CME-accredited webcast of the symposium will be available online in early 2017. Interviews with some of the symposium faculty were recorded by AAMDSIF so the presenters could...

MDS Clinical Research Consortium Meets at ASH 2016

Originally Published: 12/14/2016
Just before the active program of the annual American Society of Hematology (ASH) meeting kicked in, AAMDSIF and members of the MDS Clinical Research Consortium (MDS CRC) took the opportunity to meet with partners and friends. Several pharmaceutical researchers interested in clinical research in MDS joined the MDS CRC principal investigators for refreshments and discussion at the reception we hosted. The Cleveland Clinic’s Mikkael Sekeres. M.D., co-chair of the consortium, gave a brief presentation about the history, current operations and future plans of the CRC for event attendees. The...

MDS/AML patients benefit from novel study

Originally Published: 12/08/2016
Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility criteria, such as existing medical illnesses. A novel study at The University of Texas MD Anderson Cancer Center revealed some patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), who traditionally could not be considered for clinical trials, responded well and were safely treated in this setting. The study, led by Guillermo Garcia-Manero, M.D., professor of Leukemia, followed 109 patients with AML and MDS undergoing...
Share with